新型甘草酸制剂防治抗肿瘤药物肝损伤的现状和进展

Current situation and progression of new glycyrrhizin in the prevention and treatment of antineoplastic drug-induced liver injury

抗肿瘤药物引起的肝损伤(DILI)是临床上最常见的问题之一,日益受到重视和关注。近年来,作为抗炎类的多功能保肝药物甘草酸制剂,特别是最新一代的异甘草酸镁,已被用于防治抗肿瘤药物引起的DILI。本文拟对异甘草酸镁在血液系统肿瘤化疗、实体瘤化疗、肝动脉栓塞化疗及分子靶向治疗等多种治疗中防治DILI的应用与研究进行综述,并讨论和展望未来的发展方向。

Antineoplastic drug-induced liver injury（ DILI）, one of the most common clinical problems, has been increasingly concerned. As muhifunctional hepatoprotective drugs of anti-inflammatory class, glycyrrhizin, especially the latest glycyrrhizin magne- sium isoglycyrrhizinate, has been used for the prevention and treatment of DILl recently. This paper reviewed the current situation and research progress of magnesium isoglycyrrhizinate in the prevention and treatment of DILI in the hematological malignancy, solid tumor, hepatic artery embolism chemotherapy and molecular target therapy, and discussed the future direction of development.